Publication Listing for the MeSH term Lymphoma. Found 27 abstracts

no pagination

Publications
Bhalla, S.; Balasubramanian, S.; David, K.; Sirisawad, M.; Buggy, J.; Mauro, L.; Prachand, S.; Miller, RJ; Gordon, LI; Evens, A PCI-24781 induces caspase and reactive oxygen species-dependent apoptosis through NF-kappaB mechanisms and is synergistic with bortezomib in lymphoma cells. Clin Cancer Res (2009) 15:3354-3365.
Bultema, R.; Longnecker, RM; Swanson-Mungerson, M. Epstein-Barr virus LMP2A accelerates MYC-induced lymphomagenesis. Oncogene (2009) 28:1471-1476.
Hochster, H.; Weller, E.; Gascoyne, R. D.; Habermann, T. M.; Gordon, LI; Ryan, T.; Zhang, L.; Colocci, N.; Frankel, S.; Horning, S. J. Maintenance rituximab after cyclophosphamide, vincristine, and prednisone prolongs progression-free survival in advanced indolent lymphoma: results of the randomized phase III ECOG1496 Study. J Clin Oncol (2009) 27:1607-1614.
Mehta, J Sirolimus-Containing Graft-Versus-Host Disease Prophylaxis in Patients With Lymphoma. J Clin Oncol (2009) 27:e138; author reply e139-e138; author reply e140.
Altman, JK; Platanias, L Exploiting the mammalian target of rapamycin pathway in hematologic malignancies. Curr Opin Hematol (2008) 15:88-94.
Evens, A; Schumacker, P; Helenowski, I. B.; Singh, A. T.; Dokic, D.; Keswani, A.; Kordeluk, E.; Raji, A.; Winter, JN; Jovanovic, B. D.; Holmgren, A.; Nelson, B. P.; Gordon, LI Hypoxia inducible factor-alpha activation in lymphoma and relationship to the thioredoxin family. Br J Haematol (2008) 141:676-680.
Gerami, P; Wickless, S. C.; Rosen, S.; Kuzel, TM; Ciurea, A.; Havey, J.; Guitart, J Applying the new TNM classification system for primary cutaneous lymphomas other than mycosis fungoides and Sezary syndrome in primary cutaneous marginal zone lymphoma. J Am Acad Dermatol (2008) 59:245-254.
Hochman, N.; Houri-Haddad, Y.; Koblinski, J; Wahl, L.; Roniger, M.; Bar-Sinai, A.; Weiss, E. I.; Hochman, J. Cranberry juice constituents impair lymphoma growth and augment the generation of antilymphoma antibodies in syngeneic mice. Nutr Cancer (2008) 60:511-517.
Hoppe, R. T.; Advani, R. H.; Ambinder, R. F.; Bierman, P. J.; Bloomfield, C. D.; Blum, K.; Dabaja, B.; Djulbegovic, B.; Forero, A.; Gordon, LI; Hernandez-Ilizaliturri, F. J.; Hudson, M. M.; Kaminski, M. S.; Love, G.; Maloney, D. G.; Mansur, D.; Mauch, P. M.; Moore, J. O.; Schilder, R. J.; Weiss, L. M.; Winter, JN; Yahalom, J.; Zelenetz, A. D. Hodgkin disease/lymphoma. J Natl Compr Canc Netw (2008) 6:594-622.
Larson, A; Cook, J. R. Fibroblast growth factor receptor 3 (FGFR3) expression in malignant lymphomas. Appl Immunohistochem Mol Morphol (2008) 16:322-325.
Rovedo, M.; Longnecker, RM Epstein-Barr virus latent membrane protein 2A preferentially signals through the Src family kinase Lyn. J Virol (2008) 82:8520-8528.
Tallman, MS Introduction: evolution of targeted and multifunctional agents for leukemias and lymphomas. Semin Hematol (2008) 45:S1.
Goldman, S; Echevarria, M. E.; Fangusaro, J. Pediatric brain metastasis from extraneural malignancies: a review. Cancer Treat Res (2007) 136:143-168.
Podoloff, D. A.; Advani, R. H.; Allred, C.; Benson, AB; Brown, E.; Burstein, H. J.; Carlson, R. W.; Coleman, R. E.; Czuczman, M. S.; Delbeke, D.; Edge, S. B.; Ettinger, D. S.; Grannis, F. W. Jr; Hillner, B. E.; Hoffman, J. M.; Kiel, K.; Komaki, R.; Larson, S. M.; Mankoff, D. A.; Rosenzweig, K. E.; Skibber, J. M.; Yahalom, J.; Yu, J. M.; Zelenetz, A. D. NCCN task force report: positron emission tomography (PET)/computed tomography (CT) scanning in cancer. J Natl Compr Canc Netw (2007) 5 Suppl 1:S1-S22; quiz S23.
Shah, G. D.; Yahalom, J.; Correa, D. D.; Lai, R. K.; Raizer, J; Schiff, D.; LaRocca, R.; Grant, B.; DeAngelis, L. M.; Abrey, L. E. Combined immunochemotherapy with reduced whole-brain radiotherapy for newly diagnosed primary CNS lymphoma. J Clin Oncol (2007) 25:4730-4735.
Grimm, S; Yahalom, J.; Abrey, L. E.; DeAngelis, L. M. Retinopathy in survivors of primary central nervous system lymphoma. Neurology (2006) 67:2060-2062.
Inwards, D. J.; Cilley, J. C.; Winter, JN Radioimmunotherapeutic strategies in autologous hematopoietic stem-cell transplantation for malignant lymphoma. Best Pract Res Clin Haematol (2006) 19:669-684.
Jahnke, K.; Korfel, A.; O'Neill, B. P.; Blay, J. Y.; Abrey, L. E.; Martus, P.; Poortmans, P. M.; Shenkier, T. N.; Batchelor, T. T.; Neuwelt, E. A.; Raizer, J; Schiff, D.; Pels, H.; Herrlinger, U.; Stein, H.; Thiel, E. International study on low-grade primary central nervous system lymphoma. Ann Neurol (2006) 59:755-762.
Brem, S. S.; Bierman, P. J.; Black, P.; Blumenthal, D. T.; Brem, H.; Chamberlain, M. C.; Chiocca, E. A.; DeAngelis, L. M.; Fenstermaker, R. A.; Fine, H. A.; Friedman, A.; Glass, J.; Grossman, S. A.; Heimberger, A. B.; Junck, L.; Levin, V.; Loeffler, J. J.; Maor, M. H.; Narayana, A.; Newton, H. B.; Olivi, A.; Portnow, J.; Prados, M.; Raizer, J; Rosenfeld, S. S.; Shrieve, D. C.; Sills, A. K. Jr; Spence, A. M.; Vrionis, F. D. Central nervous system cancers: Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw (2005) 3:644-690.
Stern, J. I.; Raizer, J Primary central nervous system lymphoma. Expert Rev Neurother (2005) 5:S63-S70.

The above publications are sorted by year, faculty last name, and first author. Click on any highlighted author listed to find all publications attributed to that individual. Click on the publication title to see the abstract. First authors who are faculty are highlighted like this. Last authors who are faculty are highlighted like this. Other authors who are faculty are highlighted like this.

Lymphoma pathology therapeutic use drug therapy therapy Female Middle Aged Male genetics Aged diagnosis methods Adult Prognosis physiology metabolism immunology Treatment Outcome Antineoplastic Agents drug effects etiology Tumor Cell Line chemistry radiotherapy Antineoplastic Combined Chemotherapy Protocols administration & dosage Monoclonal Antibodies Neoplasm Staging Mice Leukemia Combined Modality Therapy Central Nervous System Neoplasms Western Blotting analysis classification Hematopoietic Stem Cell Transplantation B-Lymphocytes Neoplasms Sirolimus Brain Neoplasms Methotrexate Neoplastic Gene Expression Regulation Age Factors Apoptosis adverse effects epidemiology antagonists & inhibitors Retrospective Studies Disease-Free Survival Cultured Tumor Cells Viral Matrix Proteins Vincristine Transgenic Mice 80 and over Aged mortality Signal Transduction Kaplan-Meiers Estimate Cyclophosphamide Fibroblast Growth Factor Receptor-Type 3 Drug Delivery Systems Expert Testimony Autologous Transplantation Illinois Phytogenic Antineoplastic Agents Immunization Breast Neoplasms Risk Assessment Skin Neoplasms Magnetic Resonance Imaging Transfection Drug Dose-Response Relationship Multiple Myeloma Radioimmunotherapy Fruit AIDS-Related Lymphoma Adjuvant Chemotherapy pharmacology Flow Cytometry Differential Diagnosis Graft vs Host Disease physiopathology Non-Hodgkin Lymphoma Predictive Value of Tests Central Nervous System prevention & control Cytarabine Prednisone Beverages analogs & derivatives Immunosuppressive Agents Oligonucleotide Array Sequence Analysis Protein Binding Survival Analysis Protein Kinases Lymphocyte Activation Immunotherapy Large B-Cell Lymphoma-Diffuse Cell Cycle Radiotherapy Tertiary Protein Structure Child Clinical Trials as Topic Positron-Emission Tomography Inbred BALB C Mice Algorithms Hodgkin Disease Steroids Procarbazine Immunoconjugates Thioredoxins Kidney Neoplasms Sezary Syndrome Follow-Up Studies Adolescent bcl-X Protein Vaccinium macrocarpon Genetic Crosses Neoplasm Antigens Mouse Mammary Tumor Virus Prospective Studies Cross-Over Studies Non-Small-Cell Lung Carcinoma Virus Latency Health Status Hydroxamic Acids Cranial Irradiation Mitochondrial Membrane Potential Calcineurin Basic Helix-Loop-Helix Transcription Factors Cell Division Bone Neoplasms Remission Induction secondary surgery Disease Progression Transplantation Conditioning Antibodies Caspases Mycosis Fungoides Radiation Dose-Response Relationship Drug Therapy Drug Synergism src-Family Kinases Salvage Therapy Homologous Transplantation Boronic Acids NF-kappa B Homozygote Fluorodeoxyglucose F18 alpha Subunit Hypoxia-Inducible Factor 1